Efficacy of Centanafadine SR as a Potential Smoking Cessation Treatment

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 15, 2021

Primary Completion Date

May 31, 2022

Study Completion Date

May 31, 2022

Conditions

Smoking Cessation

Interventions

DRUG

Centanafadine

400 mg total daily dose Centanafadine Sustained Release, oral tablets

Trial Locations (2)

Rose Research Center, Raleigh

Rose Research Center, Charlotte

All Listed Sponsors

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT05066724 - Efficacy of Centanafadine SR as a Potential Smoking Cessation Treatment | Biotech Hunter | Biotech Hunter